A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

759

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Cilta-cel
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Stichting European Myeloma Network

Collaborators

[object Object]